Effectiveness of inhaled furosemide for acute asthma exacerbation: a meta-analysis by Ryota Inokuchi et al.
Inokuchi et al. Critical Care 2014, 18:621
http://ccforum.com/content/18/6/621LETTEREffectiveness of inhaled furosemide for acute
asthma exacerbation: a meta-analysis
Ryota Inokuchi1,2*†, Ai Aoki1,3,4†, Yuta Aoki1,4† and Naoki Yahagi1As the effectiveness of beta-agonists for treating asthma
attacks has been established, numerous other supportive
treatments for asthma attacks have also been investi-
gated, such as systemic glucocorticoids and magnesium.
Among these additional therapies, inhaled furosemide is
of particular interest; several studies have evaluated the
effects of prophylactic inhaled furosemide in attenuating
bronchoconstriction and asthma attacks. To determine
the efficacy of inhaled furosemide during asthma attacks,
we performed a systematic review using the MEDLINE,
EMBASE, Web of Science, and Cochrane Library data-
bases from their inception through 14 March 2014. A
meta-analysis was conducted by calculating the stan-
dardized mean difference from each study and inte-
grating these means using a random effects model. In
addition, subanalyses were performed in the studies that
evaluated the peak expiratory flow rate and the forced
expiratory volume in 1 second.
We identified six studies using double-blinded, ran-
domized control trial designs that evaluated inhaled
furosemide in conjunction with standard treatments in
patients experiencing asthma attacks [1-6] (Figure 1); a
total of 78 patients received inhaled furosemide and 79
patients received a placebo (Tables 1 and 2). The mean
age of patients ranged from 8.4 to 47 years [3,6]. In
two studies, patients were administered 40 mg inhaled* Correspondence: inokuchi-icu@h.u-tokyo.ac.jp
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unless otherwise stated.furosemide [1,2]; in one study, patients were administered
20 mg inhaled furosemide [6]; and in the three studies
that recruited children, patients were administered either
1.0 mg/kg [4,5] or 10 mg/m2 [3] inhaled furosemide.
Integrating the standardized mean difference in each
study, a random effects model showed that inhaled
furosemide had a significant positive effect on asthma
attacks (Z = 2.70; 95% confidence interval, 0.14 to 0.85;
P = 0.007) with a negligible heterogeneity (I2 = 16.82)
(Figure 2 and Table 3). Subanalyses of the studies repor-
ting the peak expiratory flow rate (Z = 2.23; P = 0.026;
n = 68/70, inhaled furosemide/placebo) and the forced
expiratory flow in 1 second (Z = 1.84; P = 0.066; n = 49/46,
inhaled furosemide/placebo) values confirmed the sig-
nificant effectiveness of inhaled furosemide for asthma
attacks (Table 3). Jackknife sensitivity analyses con-
firmed the replicability of these findings (P <0.028)
(Figure 3). No adverse events associated with furosem-
ide inhalation were reported.
These results thus reveal a statistically significant im-
provement in airflow obstruction with no evident ad-
verse events when inhaled furosemide was used as an
adjunctive treatment for acute asthma exacerbation. The
present study provides evidence supporting the addition
of inhaled furosemide to conventional treatment in cli-
nical situations.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Study selection procedure.
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Table 1 Trial characteristics
Furosemide group Placebo group





























































42 42 38 6 (N/A) 34 8 (N/A) Not >10
pack-years
Exclude 2.5 mg 40 mg 15, 30 PEFR Mild or
moderate
300
COPD, chronic obstructive pulmonary disease; FEV1.0, forced expiratory volume in 1 second; N/A, not available; PEFR, peak expiratory flow rate. aSmoking and COPD histories were not available, although no smoking
or COPD history was assumed because patients were children. bCombination treatment in all trials was simultaneous administration of a beta-agonist plus furosemide, except for Ono and colleagues, in which patients












Table 2 Trial results
Furosemide Placebo


















59.0 22.0 84.9 14.0 58.5 14.5 80.2 13.9 57.2 25.4 80.7 17.4 56.7 17.3 77.8 19.1
Nuhoğlu and colleagues,
2006 [3]






















N/A N/A 0.820 0.460 0.910 0.067 N/A N/A 0.850 0.340 0.980 0.078
Nannini and colleagues,
1992 [1]
147 68.0 269 89.7 N/A N/A 234 82.0 316 56.2 N/A N/A
Ono and colleagues,
1997 [6]
171 20.0 205 45.1 1.18 0.13 178 25.0 198 21.3 1.32 0.74 N/A
Pendino and colleagues,
1998 [2]
200 71.0 426 98.0 N/A N/A 209 68.0 337 73.2 N/A N/A











Table 3 Meta-analyses of randomized controlled trials
Number of studies Furosemide group (n) Placebo group (n) Lower 95% CI Upper 95% CI Z value P value I2
Whole studies 6 78 79 0.14 0.85 2.70 0.007 16.8
PEFR 5 68 70 0.058 0.90 2.23 0.026 30.4
FEV1.0 3 49 46 –0.027 0.83 1.84 0.066 8.16
CI, confidence interval; FEV1.0, forced expiratory volume in 1 second; PEFR, peak expiratory flow rate.
Figure 3 Jackknife sensitivity analysis, excluding one study at a time. All sensitivity analyses preserved the significant effectiveness of
inhaled furosemide for asthma attacks [1-6]. CI, confidence interval; Std, standard.
Figure 2 Meta-analysis of randomized clinical trial studies. A random effects model demonstrated significant effectiveness of inhaled
furosemide for asthma attacks [1-6]. CI, confidence interval; Std, standard.
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